|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: F10 |
Gene summary for F10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | F10 | Gene ID | 2159 |
| Gene name | coagulation factor X | |
| Gene Alias | FX | |
| Cytomap | 13q34 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P00742 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2159 | F10 | HCC1_Meng | Human | Liver | HCC | 6.87e-78 | 3.57e-01 | 0.0246 |
| 2159 | F10 | cirrhotic1 | Human | Liver | Cirrhotic | 2.77e-03 | 8.90e-02 | 0.0202 |
| 2159 | F10 | cirrhotic3 | Human | Liver | Cirrhotic | 1.74e-03 | 1.53e-01 | 0.0215 |
| 2159 | F10 | HCC1 | Human | Liver | HCC | 1.20e-15 | 4.13e+00 | 0.5336 |
| 2159 | F10 | HCC2 | Human | Liver | HCC | 3.39e-18 | 3.81e+00 | 0.5341 |
| 2159 | F10 | Pt14.a | Human | Liver | HCC | 1.58e-02 | 2.28e-01 | 0.0169 |
| 2159 | F10 | Pt14.d | Human | Liver | HCC | 1.99e-04 | 1.74e-01 | 0.0143 |
| 2159 | F10 | S014 | Human | Liver | HCC | 2.77e-40 | 2.37e+00 | 0.2254 |
| 2159 | F10 | S015 | Human | Liver | HCC | 2.15e-55 | 3.04e+00 | 0.2375 |
| 2159 | F10 | S016 | Human | Liver | HCC | 7.25e-53 | 2.29e+00 | 0.2243 |
| 2159 | F10 | S028 | Human | Liver | HCC | 1.97e-06 | 3.68e-01 | 0.2503 |
| 2159 | F10 | S029 | Human | Liver | HCC | 1.06e-10 | 5.30e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004563920 | Thyroid | HT | positive regulation of myeloid cell differentiation | 17/1272 | 103/18723 | 5.50e-04 | 6.52e-03 | 17 |
| GO:19021078 | Thyroid | HT | positive regulation of leukocyte differentiation | 22/1272 | 157/18723 | 9.54e-04 | 9.83e-03 | 22 |
| GO:19037088 | Thyroid | HT | positive regulation of hemopoiesis | 22/1272 | 157/18723 | 9.54e-04 | 9.83e-03 | 22 |
| GO:003166826 | Thyroid | HT | cellular response to extracellular stimulus | 30/1272 | 246/18723 | 1.34e-03 | 1.29e-02 | 30 |
| GO:003166926 | Thyroid | HT | cellular response to nutrient levels | 27/1272 | 215/18723 | 1.49e-03 | 1.38e-02 | 27 |
| GO:00027635 | Thyroid | HT | positive regulation of myeloid leukocyte differentiation | 10/1272 | 58/18723 | 5.30e-03 | 3.51e-02 | 10 |
| GO:000257320 | Thyroid | HT | myeloid leukocyte differentiation | 24/1272 | 208/18723 | 7.69e-03 | 4.54e-02 | 24 |
| GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
| GO:0008380113 | Thyroid | PTC | RNA splicing | 273/5968 | 434/18723 | 4.44e-41 | 1.40e-37 | 273 |
| GO:0000375113 | Thyroid | PTC | RNA splicing, via transesterification reactions | 202/5968 | 324/18723 | 6.81e-30 | 3.91e-27 | 202 |
| GO:0000377113 | Thyroid | PTC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
| GO:0000398113 | Thyroid | PTC | mRNA splicing, via spliceosome | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
| GO:1903311112 | Thyroid | PTC | regulation of mRNA metabolic process | 181/5968 | 288/18723 | 1.60e-27 | 5.94e-25 | 181 |
| GO:0034976113 | Thyroid | PTC | response to endoplasmic reticulum stress | 161/5968 | 256/18723 | 1.14e-24 | 3.27e-22 | 161 |
| GO:0050684112 | Thyroid | PTC | regulation of mRNA processing | 98/5968 | 137/18723 | 1.53e-21 | 3.10e-19 | 98 |
| GO:0043484113 | Thyroid | PTC | regulation of RNA splicing | 102/5968 | 148/18723 | 2.03e-20 | 3.21e-18 | 102 |
| GO:0097193113 | Thyroid | PTC | intrinsic apoptotic signaling pathway | 164/5968 | 288/18723 | 9.17e-19 | 1.09e-16 | 164 |
| GO:0051098113 | Thyroid | PTC | regulation of binding | 195/5968 | 363/18723 | 3.21e-18 | 3.37e-16 | 195 |
| GO:1902903113 | Thyroid | PTC | regulation of supramolecular fiber organization | 202/5968 | 383/18723 | 1.16e-17 | 1.15e-15 | 202 |
| GO:001657010 | Thyroid | PTC | histone modification | 235/5968 | 463/18723 | 1.17e-17 | 1.15e-15 | 235 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| TNFSF10 | TNFRSF10A | TNFSF10_TNFRSF10B | TRAIL | Cervix | CC |
| TNFSF10 | TNFRSF10A | TNFSF10_TNFRSF10B | TRAIL | CRC | MSI-H |
| TNFSF10 | TNFRSF10A | TNFSF10_TNFRSF10B | TRAIL | CRC | MSS |
| TNFSF10 | TNFRSF10A | TNFSF10_TNFRSF10B | TRAIL | Lung | AAH |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| F10 | SNV | Missense_Mutation | novel | c.260N>T | p.Gly87Val | p.G87V | P00742 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| F10 | SNV | Missense_Mutation | novel | c.240N>A | p.Phe80Leu | p.F80L | P00742 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| F10 | SNV | Missense_Mutation | rs121964941 | c.1120T>C | p.Ser374Pro | p.S374P | P00742 | protein_coding | deleterious(0.03) | possibly_damaging(0.511) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| F10 | SNV | Missense_Mutation | c.8N>A | p.Arg3His | p.R3H | P00742 | protein_coding | tolerated_low_confidence(0.16) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| F10 | SNV | Missense_Mutation | c.860N>T | p.Arg287Met | p.R287M | P00742 | protein_coding | tolerated(0.11) | probably_damaging(0.95) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| F10 | insertion | Frame_Shift_Ins | novel | c.950_951insCAGCCTGTTGAGGTTTGCGATTCTTGTTTCCTGGTTCGAGTCTT | p.Glu317AspfsTer16 | p.E317Dfs*16 | P00742 | protein_coding | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| F10 | insertion | In_Frame_Ins | novel | c.958_959insGGCCTC | p.Asp320delinsGlyProHis | p.D320delinsGPH | P00742 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| F10 | insertion | Nonsense_Mutation | novel | c.959_960insTCTGCATCTTTAGGAAGAATGGTTGGTGTTCGTGT | p.Phe321LeufsTer4 | p.F321Lfs*4 | P00742 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| F10 | insertion | Nonsense_Mutation | novel | c.987_988insTATACATTTTAAAATATAAA | p.Thr330TyrfsTer4 | p.T330Yfs*4 | P00742 | protein_coding | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| F10 | SNV | Missense_Mutation | rs201675411 | c.1016C>T | p.Ala339Val | p.A339V | P00742 | protein_coding | tolerated(1) | benign(0.147) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | Apixaban | APIXABAN | ||
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | BIBT986 | TANOGITRAN | ||
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | Trimidox | TRIMETHOPRIM/SULFADOXINE | ||
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | Emicizumab | EMICIZUMAB | ||
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | PRT4445 | |||
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 405067325 | OTAMIXABAN | |
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | SR-123781A | |||
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | CHEMBL1908371 | IDRAPARINUX SODIUM | |
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | FACTOR IX | |||
| 2159 | F10 | DRUGGABLE GENOME, PROTEASE, ENZYME | ANTITHROMBIN |
| Page: 1 2 3 4 5 6 7 8 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |